Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 3

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

NCT07339423 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Conditions Studied

Interventions

  • DRUG NNC0487-0111
  • DRUG Placebo (matched to NNC0487-0111)

Study Locations (20)

North Carolina

  • UNC Eastowne Medical Office — Chapel Hill
  • PharmQuest Life Sciences LLC — Greensboro
  • Accellacare — Wilmington

South Carolina

  • Medical Uni of SC Charleston — Charleston
  • Coastal Carolina Research Ctr — North Charleston
  • Hillcrest Clinical Research — Simpsonville

Texas

  • Amarillo Medical Specialists — Amarillo
  • Velocity Clinical Res-Dallas — Dallas
  • Care United Research, LLC — Forney

Florida

  • South Broward Research LLC — Miramar
  • Clinical Neuroscience Solution — Orlando

Virginia

  • Washington Cntr Weight Mgmt — Arlington
  • Health Res of Hampton Roads — Newport News

Georgia

  • Hope Clin Res & Wellness — Conyers

Illinois

  • Endeavor Health — Skokie

Indiana

  • Midwest Inst For Clin Res — Indianapolis

Trial Details

FieldValue
Enrollment Target 1,150 participants
Start Date 2026-02-24
Est. Completion 2029-08-21
Phase Phase 3

Sponsor

Novo Nordisk A/S

189 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07339423

The ClinicalTrials.gov registry entry for NCT07339423 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 189 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions — of which NNC0487-0111 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07339423 reports 20 study locations spanning 12 distinct geographic areas — top geographies include North Carolina, South Carolina, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07339423 about?

NCT07339423 is a clinical study titled "AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight". The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) o...

What is the current status of trial NCT07339423?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2026-02-24. Estimated completion is 2029-08-21.

What conditions does trial NCT07339423 study?

This clinical trial studies the following conditions: Obesity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07339423?

The interventions under investigation include: NNC0487-0111 (DRUG), Placebo (matched to NNC0487-0111) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07339423?

This trial is sponsored by Novo Nordisk A/S, which has 189 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07339423 being conducted?

This trial has 20 study locations across Florida, Georgia, Illinois, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial